Related Experiment Video
Updated: Dec 6, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania
Olivia F Hunter1,2, Furaha Kyesi3, Amrit Kaur Ahluwalia4
1Dartmouth College, Hanover, NH, 03755, USA. olivia.frances.hunter@gmail.com.
Insights
Isoniazid preventive therapy (IPT) for children living with HIV in Tanzania showed high adherence and completion rates when integrated into routine care. This study demonstrates IPT is feasible and well-tolerated in this population.
Area of Science:
- Pediatric infectious diseases
- Public health interventions
- HIV/AIDS management
Background:
- Tuberculosis (TB) prevention guidelines recommend isoniazid preventive therapy (IPT) for children aged 12 months and older living with HIV.
- Global uptake of IPT in children is limited by concerns regarding tolerability, adherence, and potential mistreatment of undiagnosed TB.
- Diagnostic confirmation of TB in children presents significant challenges.
Purpose of the Study:
- To assess the implementation and adherence of isoniazid preventive therapy (IPT) in a pediatric HIV clinic in Tanzania.
- To evaluate the feasibility and tolerability of a 6-month daily isoniazid regimen for children living with HIV.
- To determine treatment completion rates and adherence levels for IPT in this vulnerable population.
Main Methods:
- Prospective cohort study involving 66 children aged 1-15 years living with HIV who screened negative for TB disease.
- Offered a 6-month daily isoniazid regimen, with options for facility- or community-based care.
- Adherence and completion determined by pill counts, appointment attendance, and self-report; TB symptom screening at all visits.
Main Results:
- No participants declined IPT; 74.2% completed the 6-month regimen within 10 months.
- High average monthly adherence of 98.0% among completers.
- IPT was well-tolerated, with only 11 participants discontinuing due to adverse drug reactions; no TB cases were detected during or after IPT.
Conclusions:
- High adherence and treatment completion rates are achievable when IPT is integrated into routine, facility-based pediatric HIV care.
- IPT is well-tolerated and effective in preventing TB in children living with HIV.
- IPT implementation is feasible in Tanzania and should be widely adopted for pediatric HIV care.
Background:
In accordance with international guidance for tuberculosis (TB) prevention, the Tanzanian Ministry of Health recommends isoniazid preventive therapy (IPT) for children aged 12 months and older who are living with HIV. Concerns about tolerability, adherence, and potential mistreatment of undiagnosed TB with monotherapy have limited uptake of IPT globally, especially among children, in whom diagnostic confirmation is challenging. We assessed IPT implementation and adherence at a pediatric HIV clinic in Tanzania.
Methods:
In this prospective cohort study, eligible children living with HIV aged 1-15 years receiving care at the DarDar Pediatric Program in Dar es Salaam who screened negative for TB disease were offered a 6-month regimen of daily isoniazid. Patients could choose to receive IPT via facility- or community-based care. Parents/caregivers and children provided informed consent and verbal assent respectively. Isoniazid was dispensed with the child's antiretroviral therapy every 1-3 months. IPT adherence and treatment completion was determined by pill counts, appointment attendance, and self-report. Patients underwent TB symptom screening at every visit.
Results:
We enrolled 66 children between July and December 2017. No patients/caregivers declined IPT. Most participants were female (n = 43, 65.1%) and the median age was 11 years (interquartile range [IQR] 8, 13). 63 (95.5%) participants chose the facility-based model; due to the small number of participants who chose the community-based model, valid comparisons between the two groups could not be made. Forty-nine participants (74.2%) completed IPT within 10 months. Among the remaining 17, 11 had IPT discontinued by their provider due to adverse drug reactions, 5 lacked documentation of completion, and 1 had unknown outcomes due to missing paperwork. Of those who completed IPT, the average monthly adherence was 98.0%. None of the participants were diagnosed with TB while taking IPT or during a median of 4 months of follow-up.
Conclusions:
High adherence and treatment completion rates can be achieved when IPT is integrated into routine, self-selected facility-based pediatric HIV care. Improved record-keeping may yield even higher completion rates. IPT was well tolerated and no cases of TB were detected. IPT for children living with HIV is feasible and should be implemented throughout Tanzania.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Sexually Transmitted Infections

